FAQ on Polyrizon Ltd.'s $4.2M Initial Public Offering and Its Innovative Medical Device Hydrogels
Summary
What is Polyrizon Ltd. and what does it specialize in?
Polyrizon Ltd. is a development-stage biotech company specializing in the development of innovative medical device hydrogels, delivered as nasal sprays, designed to form a barrier against viruses and allergens.
How much did Polyrizon Ltd. raise in its initial public offering?
Polyrizon Ltd. raised $4.2 million in its initial public offering, with the potential to increase to approximately $4.82 million if the over-allotment option is fully exercised.
What is the price per unit in Polyrizon’s IPO?
The price per unit in Polyrizon’s IPO was $4.38.
Who managed Polyrizon Ltd.’s initial public offering?
Aegis Capital Corp. acted as the sole book-running manager for Polyrizon Ltd.’s initial public offering.
What is Polyrizon’s Capture and Contain (C&C) hydrogel technology?
Polyrizon’s Capture and Contain (C&C) hydrogel technology is a proprietary mixture of naturally occurring building blocks delivered as nasal sprays, forming a thin shield containment barrier in the nasal cavity to protect against viruses and allergens.
What is the potential application of Polyrizon’s technology?
Polyrizon’s technology has potential applications as a ‘biological mask’ for protection against viruses and allergens, and for the intranasal delivery of drugs.
Where can I find more information about Polyrizon Ltd.’s IPO?
More information about Polyrizon Ltd.’s IPO can be found in the full press release at https://ibn.fm/S0rSC.
What is the significance of Polyrizon’s initial public offering?
The initial public offering provides Polyrizon with the necessary funds to advance its innovative hydrogel technology, which could have significant implications for protection against viruses and allergens and drug delivery.
Who provided legal counsel for Polyrizon’s IPO?
Greenberg Traurig acted as counsel to Polyrizon, and Sichenzia Ross Ference Carmel LLP acted as counsel to Aegis Capital Corp. for the IPO.
This story is based on an article that was registered on the blockchain. The original source content used for this article is located at InvestorBrandNetwork (IBN)
Article Control ID: 124962